Best Life Sciences Companies in Sweden
The 703 best Life Sciences companies in Sweden in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Hansa Biopharma.
Sweden's Life Sciences sector is moving fast, and this directory ranks 703 companies across it by disclosed equity funding and recent funding momentum. Total disclosed capital sits at $2.2B. No unicorns yet, but Hansa Biopharma has pulled in $286M, Anocca another $120M, and Cereno Scientific $32M — that's a credible cluster of late-stage bets forming in one geography. Investors like Almi Invest, EIC Fund, and Uppsala Innovation Centre keep showing up across the cap table, which tells you something about where the conviction is concentrated.
So what's the broader pull? The global Life Sciences market is tracking a 10.2% CAGR, with aging populations and funding momentum as the core demand engines. I'd also watch the IPO signal: SAI Life Sciences filing a fresh-issue IPO is the kind of move that tells you institutional appetite for the sector is real right now. Meanwhile, Asahi Songwon's API acquisition points to consolidation happening across the value chain globally. Sweden's companies are building into that current, not against it.
- Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Sweden
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Hansa Biopharma Developer of therapeutics to treat rare immunological diseases | $286M | 2 mo ago | Public | 162 | Soren Tulstrup President & Ceo | Top 5M | 108 patents Patents concentrated in health & consumer products | — |
| 2 | Anocca Deevloper of personalized immunotherapeutics for oncology, autoimmune and inflammatory diseases | $120M | 9 mo ago | Series D | 100 | — | Top 50M | — | — |
| 3 | BONESUPPORT Injectable, synthetic bone substitutes for remodeling | $101M | 115 mo ago | Public | 24 | Emil Billback CEO | Top 5M | — | 2 partnerships |
| 4 | OxThera Provider of microbial-based drug products to treat hyperoxaluria | $93M | 81 mo ago | Series D | 21 | — | — | — | — |
| 5 | ITBMed Developer of monoclonal antibodies to prevent transplant rejections | $87M | 54 mo ago | Series A | 28 | David Sachs Co-Founder | Top 50M | — | — |
| 6 | Immunovia Developer of protein diagnostics devices for the early detection of cancer | $57M | 72 mo ago | Public | 45 | Jeff Borcherding Chief Executive Officer | Top 10M | 173 patents Diagnostic biomarker arrays for cancer and autoimmune disease detection | 1 job opening · 1 launch |
| 7 | Affibody Developer of antibody mimetic and protein based drug for the treatment of multiple diseases | $43M | 41 mo ago | Series D | 113 | — | Top 10M | 422 patents Peptide therapeutics targeting cytokine/receptor pathways for immuno‑oncology and inflammation | 1 launch |
| 8 | Tribune Therapeutics Developer of therapeutics for fibrotic diseases | $41M | 14 mo ago | Series A | 9 | Havard Attramadal Co-Founder | Top 50M | 5 patents Therapeutic agents targeting CCN protein signaling pathways for disease treatment | — |
| 9 | Asgard Therapeutics Developer of cancer immunotherapeutic solutions based on direct cell reprogramming | $40M | 27 mo ago | Series A | 7 | Cristiana Pires Co-Founder & CEO | Top 10M | 36 patents Cellular reprogramming to dendritic/antigen‑presenting cells for cancer immunotherapy | 1 job opening · 1 award |
| 10 | EnginZyme Developer of immobilized enzymes | $35M | 41 mo ago | Series B | 59 | Samuel Hargestam Co-Founder | — | 48 patents Patents concentrated in chemistry & materials | 1 partnership |
| 11 | Cereno Scientific Developer of therapeutics for cardiovascular diseases | $32M | 6 mo ago | Public | — | Sten Sorensen CEO | Top 10M | — | — |
| 12 | Elypta Provider of liquid biopsy-based molecular diagnostics for cancer detection | $28M | 47 mo ago | Series A | 27 | Karl Bergman CEO | Top 50M | 25 patents Diagnostic biomarkers for cancer and arthritic disease detection and discrimination | 1 partnership |
| 13 | Moleculent Provider of a biology platform that detects cell-cell interactions within their tissue environment | $26M | 1 mo ago | Series A | — | Olle Ericsson Founder and CEO | Top 10M | 24 patents Spatially resolved in situ biomolecular assay and detection platforms for planar samples | — |
| 14 | PharmNovo Developer of a novel drug for neuropathic pain relief solutions | $21M | 23 mo ago | Series A | 9 | Bengt Mentzer Founder & President | — | 25 patents Delta opioid receptor agonist small molecules and their hydrochloride salt polymorphs | 1 launch |
| 15 | OssDsign Developer of regenerative 3D-printed orthopedic implants for craniofacial bone defects and trauma | $20M | 12 mo ago | Public | 50 | — | Top 10M | 89 patents Bone repair implants and bioactive cements for filling defects and bore holes. | 1 launch |
| 16 | Umecrine Cognition Developer of therapeutics for hepatic encephalopathy | $18M | 13 mo ago | Series A | 3 | Viktor Drvota CEO | — | 117 patents Neurosteroid GABAA‑α3 modulators and their pharmaceutical formulations | — |
| 17 | BioLamina Cell culture reagents for stem cell research | $18M | 2 mo ago | Series B | 75 | Magnus Kenneby Co-Founder | Top 5M | 134 patents Stem cell differentiation methods for retinal pigment epithelium and dopaminergic cells | — |
| 18 | Sigrid Therapeutics Developer of therapies to treat metabolic and chronic lifestyle diseases | $18M | 5 mo ago | Series C | 17 | Sana Alajmovic Co-Founder & CEO | Top 10M | 50 patents Porous silica particles for oral drug delivery, supplements, and dental care formulations. | 1 launch |
| 19 | AnaCardio Developer of drugs for heart failure treatment | $17M | 17 mo ago | Series A | 11 | Lars Lund Founder | — | 32 patents Cardiac inotropic therapeutics using piperidine‑urea compounds for acute heart failure | 1 expansion |
| 20 | One-carbon Therapeutics Developer of therapeutics to treat cancers, inflammation, and autoimmune diseases | $16M | 6 mo ago | Series B | 3 | — | — | — | — |
| 21 | Single Technologies Developer of a technology platform for single-molecule imaging | $8M | 27 mo ago | Series A | 24 | — | — | — | — |
| 22 | Rarity Bioscience Developer of assays for diagnostics of cancer | $8M | 24 mo ago | Series A | 9 | Per Matsson Co-chair & co-founder | Top 50M | 14 patents Sensitive nucleic acid detection assays using variant-specific probes and blocking agents | 2 awards |
| 23 | Cellevate Developer of nanofiber-based cell culture products for upstream bioprocessing | $7M | 21 mo ago | Seed | 20 | Maximilian Ottosson Founder & COO | Top 50M | 14 patents Nanofibrous scaffolds enabling industrial-scale cell and viral biomanufacturing | — |
| 24 | VERIGRAFT Developer of personalized tissue-engineered transplants | $6M | 16 mo ago | Funding Raised | 12 | Petter Bjorquist CEO | — | 46 patents Personalized bioengineered nerve and blood vessel grafts for regenerative surgery | 2 partnerships · 1 award |
| 25 | Melt&Marble Platform offering plant-based meat alternative products | $6M | 6 mo ago | Series A | 20 | Florian David Co-Founder | Top 50M | 22 patents Patents concentrated in chemistry & materials | — |
| 26 | Beactica Develops small molecule drugs for oncology | $5M | 3 mo ago | Series A | 17 | — | Top 50M | — | — |
| 27 | Alba Health Provider of personalized nutrition plans and coaching services for children | $5M | 12 mo ago | Seed | — | Willem De Vos Co-Founder | Top 5M | — | — |
| 28 | TIRmed Pharma Developer of therapeutic solutions to treat atopic dermatitis | $5M | 14 mo ago | Series A | — | Anna Spetz Founder & CEO | — | 20 patents Antisense single‑stranded oligonucleotide therapeutics for viral and dermatological diseases | 1 award |
| 29 | Observe Medical A single use, digital urine meter which measures biofilm build-up | $5M | 9 mo ago | Public | 17 | — | Top 50M | — | 2 job openings · 1 partnership |
| 30 | Realheart Developer of artificial heart for heart failure patients | $4M | 29 mo ago | Funding Raised | 11 | — | Top 10M | — | 1 award |
| 31 | MedVasc Providing a surgical tool for intraoperative drug delivery | $4M | 4 mo ago | Series A | 4 | Michael Akesson Founder | — | 15 patents Intravascular and cavity ablation devices for treating defective vessels, cavities, and ducts | — |
| 32 | Cytely Provider of smart microscopy solution for biomedical research | $3M | 7 mo ago | Series A | — | Johannes Ahnlide Co-Founder & CTO | Top 50M | 2 patents Automated selection of microscopy image subsets for digital image analysis | 1 launch |
| 33 | Amferia Developer of an anti-infective technology | $3M | 6 mo ago | Series B | 7 | Anand Rajasekharan Co-Founder & CEO | Top 50M | 37 patents Advanced wound-care devices, bioactive dressings, and endotoxin‑neutralizing biomaterials | — |
| 34 | Elicera Developer of drugs for immuno-oncology | $3M | 16 mo ago | Funding Raised | 2 | Di Yu Co-Founder | Top 50M | — | — |
| 35 | AlzeCure Pharma Developer of therapeutics for neurological disorders | $3M | 6 mo ago | Funding Raised | 11 | — | Top 10M | 68 patents Patents concentrated in chemistry & materials | 5 partnerships |
| 36 | Avidicare Provider of ventilation systems designed for infection control in healthcare | $3M | 12 mo ago | Seed | — | Peter Hojerback CEO | Top 50M | 23 patents Cleanroom and medical air supply/ventilation system design and control | — |
| 37 | Umecrine Developer of drugs to treat neurological disorders of the brain | $2M | 17 mo ago | Seed | — | Torbjorn Backstrom CEO | — | 72 patents Steroid-based compounds targeting GABAA α3 receptor modulation for neurotherapeutics | — |
| 38 | Thioredoxin Systems Developer of antibiotics against pathogenic bacteria | $2M | 19 mo ago | Early Stage | 5 | Arne Holmgren Founder | — | 17 patents Antimicrobial formulations combining silver ions with selenium/ebselen compounds | — |
| 39 | Epigenica Provider of solutions for the analysis of genomic data | $2M | 11 mo ago | Seed | — | Simon Alsatian Co-Founder | — | 14 patents Multiplexed cfDNA sequencing and chromatin modification profiling for epigenetic analysis | — |
| 40 | Uman Sense Developer of wearable device for stroke detection | $2M | 21 mo ago | Seed | 9 | Johan Wasselius Co-Founder | — | 9 patents Physiological sensor systems for rapid stroke detection in patients | — |
| 41 | BrainZell Developer of lab-grown cell based models of the human brain for drug development | $1M | 21 mo ago | Seed | 2 | Robin Pronk Co-Founder | — | — | — |
| 42 | Lithea Developer of bone mineral platform for local cancer drug delivery | $989K | 7 mo ago | Seed | — | Deepak Raina Co-Founder & CTO | — | — | — |
| 43 | Aligned Bio Provider of nanowire-based sensors | $909K | 21 mo ago | Seed | 17 | Jaime Castillo-Leon Co-Founder & Director | Top 50M | — | — |
| 44 | Proteomedge Provider of protein standards for mass spectrometry-based quantification in blood plasma | $856K | 2 mo ago | Seed | — | Kalle Von Feilitzen Co-Founder | Top 50M | 12 patents Standard protein reference materials for quantitative proteomics and analytical assays | 2 partnerships |
| 45 | Xaga Surgical Manufacturer of medical needles | $727K | 16 mo ago | Seed | 3 | Anna Lindstrom Co-Founder | — | 33 patents Patents concentrated in health & consumer products | — |
| 46 | AAX Biotech Developer of immunotherapies for cancer and autoimmune therapies | $685K | 3 mo ago | Seed | — | Maria Knudsen CEO | Top 50M | 2 patents Therapeutic agent and target binding site discovery and design in biotechnology | — |
| 47 | LayerLogic Developer of biosensing technology for rapid bacteria, virus, fungi, detection | $541K | 12 mo ago | Seed | — | Avgust Yurgens Co-Founder | Top 50M | 2 patents Scalable manufacturing of graphene materials for large‑area electronic and composite applications | 1 award |
| 48 | NEOGAP Developer of radiopharmaceuticals for the treatment of cancer | $473K | 4 mo ago | Series A | 21 | Samuel Svensson CEO | Top 50M | — | — |
| 49 | Lead Biologics Developer of therapeutic antibodies against cancer | $259K | 10 mo ago | Seed | — | Thoas Fioretos Co-Founder | — | 5 patents Therapeutic and diagnostic antibodies targeting specific antigens | — |
Top 12 Life Sciences companies in Sweden
#1
Public · Lund, Skane County · founded 2007 · 162 employees$286.5Mraised▾
Developer of therapeutics to treat rare immunological diseases. The company is developing and commercializing immunomodulating therapies across transplantation, autoimmune diseases, gene therapy, and oncology indications.
- Mar 2026Post IPO$30M
- Jul 2022Post IPO$70M
- Jul 2020Post IPO$121M
- Nov 2017Post IPO$65.5M
#2
Series A · Solna, Stockholm County · founded 2019$26Mraised▾
Provider of a biology platform that detects cell-cell interactions within their tissue environment. It offers functional profiling platform that allows scientists to map cell-cell communication directly in clinical tissue, providing insights of the cellular complexity in health and disease.
- May 2026Series A$20M
- Jun 2024Series A$26M
#3
Series B · Sundbyberg, Stockholm County · founded 2008 · 75 employees$18.2Mraised▾
BioLamina is a biotechnology company that manufactures full-length human recombinant laminins for primary and stem-cell culture applications. The company's product portfolio includes recombinant laminins as cell culture matrices for specific uses like pluripotent stem cell culture, early epithelial development and differentiation, and kits with multiple laminins for screening the most appropriate matrix for specific cell types.
- Apr 2026Conventional Debt$23.6M
- Sep 2023Series B$18.2M
- Apr 2021Grant (prize money)$444.3K
- Aug 2009Grant (prize money)$331.6K
#4
Series D · Sodertalje, Stockholm County · founded 2014 · 100 employees$120Mraised▾
Developer of personalized immunotherapeutics for oncology, autoimmune and inflammatory diseases. The company has TCR-modified T-cell therapies against multiple antigen classes, tumours, genetic mutations, and viruses that cause cancer. The proprietary Immuno-technology platform for its target discovery, validation, and product development.
- Aug 2025Series D$46M
- May 2023Series C$36.9M
- Dec 2022Venture Debt$26.5M
- Jul 2021Series B$47M
#5
Series C · Stockholm, Stockholm County · founded 2014 · 17 employees$17.5Mraised▾
Developer of therapies to treat metabolic and chronic lifestyle diseases. The company has developed a material platform technology, SiPore an orally administered silica-based powder product. It has multiple applications including gestational and pediatric type 2 diabetes and obesity, modulation of the gut microbiome, treatment of excessive bile acid levels post-bariatric surgery, NASH, weight loss, and infantile colic.
- Jan 2026Series C$5M
- Oct 2023Series B$4M
- Jan 2023Series A$1M
- Nov 2021Series A$8.4M
#6
Public · Askim, Vastra Gotaland · founded 2012$31.6Mraised▾
Developer of therapeutics for cardiovascular diseases. It offers a lead candidate CS a well-tolerated oral therapy for pulmonary arterial hypertension, CS014 for idiopathic pulmonary fibrosis, and CS585 an oral, highly potent and selective prostacyclin receptor agonist for pulmonary hypertension.
- Nov 2025Post IPO$31.6M
#7
Series A · Uppsala, Uppsala County · founded 2006 · 17 employees$5.1Mraised▾
Beatica develops small molecule drug discovery platforms. Its proprietary platform is based on surface plasmon resonance and is designed to predict molecule - target interaction, especially when protein crystallization is not possible. The company offers lead optimization and other drug discovery services to pharma companies and research organizations. In addition, Beatica is planning to develop an internal pipeline of its own molecules as well.
- Feb 2026Grant (prize money)$3M
- Dec 2019Grant (prize money)$326.3K
- Jun 2019Series A—
- Sep 2018Grant (prize money)$58K
#8
Series B · Stockholm, Stockholm County · founded 2019 · 3 employees$16.2Mraised▾
Developer of therapeutics to treat cancers, inflammation, and autoimmune diseases. It offers one-carbon metabolism pathway-based therapeutics that target DNA repair and DNA damage response for the treatment of BRCA mutated cancer with PARP inhibitors.
- Dec 2025Series B$16.2M
#9
Series A · Gothenburg, Vastra Gotaland County · founded 2014 · 20 employees$6.2Mraised▾
Platform offering plant-based meat alternative products. The company uses precision fermentation to create animal fats. It uses synthetic biology and metabolic engineering allowing to build of proprietary yeast strains. Its microbial metabolism can dictate the structure and properties of the fats that the microbes are producing, allowing to mimic the fat structure.
- Dec 2025Series A$8.5M
- Jul 2024Grant (prize money)$3M
- May 2022Seed$5.3M
- Aug 2021Seed$876.3K
#10
Series A · Lund, Skane County · founded 2013 · 4 employees$3.7Mraised▾
MedVASC AB is providing a surgical tool for intraoperative drug delivery. They made a single cut through laser or catheter then puncture the vein wall through an anesthetic needle to numb the surrounding tissue. Through the fast treatment, surgery time is reduced by a half.
- Jan 2026Series A$2.6M
- May 2025Seed$1M
#11
Series B · Gothenburg, Vastra Gotaland County · founded 2018 · 7 employees$3.5Mraised▾
Amferia is developing an anti-infective technology. The company has developed its proprietary patented technology which consists of anti-bacterial polymers that can kill bacteria including antibiotic-resistant bacteria. The material is selective and targets only bacteria and is non-toxic to human cells.
- Dec 2025Series B$4.1M
- Sep 2024Series A$1.3M
- Jan 2023Series A$1.5M
- Feb 2020Grant (prize money)$55K
#12
Public · Uppsala, Uppsala County · founded 2011 · 50 employees$19.7Mraised▾
Developer of regenerative 3D-printed orthopedic implants for craniofacial bone defects and trauma. Its implants incorporate a proprietary calcium phosphate-based material composition, reinforced by titanium, and CAD-based manufacturing and design. It uses 3D printing technologies to produce implants using materials like titanium combined with cured ceramic tiles. Its products have applications in the reconstruction of facial bone after trauma, tumor resection or growth retardation due to irradiation, and the repair of hereditary facial defects such as paranasal augmentation in cleft patients and correction of hemifacial microsomia.
- Jun 2025Post IPO$16.5M
- Sep 2023Post IPO$13.6M
- Feb 2019Series A$6.9M
- Sep 2017Grant (prize money)—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Sweden
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 299 Sweden-affiliated papers.
- Swedish University of Agricultural Sciences53
- Karolinska Institutet52
- Uppsala University33
- Science for Life Laboratory29
- University of Gothenburg28
- Messenger RNA1→7
- Transcription (linguistics)1→4
- Gene4→5
- Gene1→5
- Antibody1→5
- Antibiotic resistance3
- Antibiotics3
- Agriculture3
- Production (economics)3
- Antimicrobial2
Where biotechnology is researched across Sweden
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.